DiaSorin updates assay to detect omicron variant

By LabPulse.com staff writers

January 14, 2022 -- DiaSorin Molecular recently released an updated version of its Simplexa Variants Direct assay to detect mutations associated with the new omicron variant of SARS-CoV-2.

The assay helps with preselection of positive samples that would benefit from further sequencing which in turn helps with monitoring programs for the spread of concerning variants.

The assay is for research use only and is not for use in diagnostics procedures. It works directly on nasopharyngeal and nasal swab specimens that were identified as positive for SARS-CoV-2. It also allows for in vitro qualitative detection of the mut

Qiagen, DiaSorin partner on TB screening
The U.S. Food and Drug Administration has approved Qiagen's Liaison QuantiFeron-TB Gold Plus assay for use on DiaSorin's automated Liaison XS platform....
DiaSorin completes Luminex acquisition for $1.8B
DiaSorin has completed its acquisition of Luminex in a deal valued at $1.8 billion. The acquisition gives DiaSorin access to Luminex's multiplexing...
Qiagen, DiaSorin debut Lyme disease assay
Qiagen and DiaSorin announced the launch of the Liaison LymeDetect assay for early detection of the Lyme Borreliosis infection. The test detects immunoglobulin...
Labcorp adds new COVID-19 antigen test to repertoire
Labcorp has added a new high sensitivity antigen test for screening for active COVID-19 disease to its testing offerings. The nasal swab test was developed...
A look at how COVID-19 testing varies by world region
While demand for COVID-19 testing has grown globally, the testing situation differs from region to region, writes Justin Saeks, an analyst with market...

Copyright © 2022 LabPulse.com

Last Updated ls 1/14/2022 2:48:12 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current